Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(1.57)
# 3,200
Out of 4,843 analysts
54
Total ratings
20.83%
Success rate
-8.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $8.17 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $15.02 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $1.46 | - | 1 | Mar 18, 2025 | |
| MTSR Metsera | Initiates: Overweight | n/a | $26.72 | - | 1 | Feb 25, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $14.15 | - | 3 | Jan 21, 2025 | |
| ATYR aTyr Pharma | Initiates: Overweight | n/a | $4.47 | - | 1 | Jan 6, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $5.00 | +100.00% | 1 | Dec 17, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $275.26 | - | 4 | Nov 20, 2024 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $21.76 | +198.71% | 12 | Sep 23, 2024 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Overweight | n/a | $39.01 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $49.65 | - | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.89 | - | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $35.11 | -31.64% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.45 | +18,267.35% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $0.39 | +3,489.74% | 1 | Mar 3, 2021 |
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.17
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $15.02
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.46
Upside: -
Metsera
Feb 25, 2025
Initiates: Overweight
Price Target: n/a
Current: $26.72
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $14.15
Upside: -
aTyr Pharma
Jan 6, 2025
Initiates: Overweight
Price Target: n/a
Current: $4.47
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $5.00
Upside: +100.00%
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $275.26
Upside: -
Structure Therapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: $65
Current: $21.76
Upside: +198.71%
MoonLake Immunotherapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $39.01
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $49.65
Upside: -
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.89
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $35.11
Upside: -31.64%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.45
Upside: +18,267.35%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $0.39
Upside: +3,489.74%